Epigral (EPIGRAL.NS) Stock Price

Epigral Price

BSE·CLOSED
1,004.00
​
Market closed

Revenue has compounded at 23.0% per year over the past 7 years to 25.50 B INR. Earnings per share have grown at 13.0% per year over the last 7 years. Epigral's net margin stands at 14.0%, up from 12.2% several years earlier. Epigral currently offers a dividend yield of about 0.60%. The payout ratio is around 7% of earnings. The dividend has grown at 9.5% per year over the past 2 years. Analysts set a median price target of 2,040.00 INR, implying 103.2% above the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.

Epigral stock price

Access this data via the Eulerpool API

Epigral business model & stock analysis

Meghmani Finechem Ltd. engages in the manufacture of chemicals involved in pigments and pesticides. The company is headquartered in Ahmedabad, Gujarat and currently employs 936 full-time employees. The company went IPO on 2021-08-18. The firm is engaged in manufacturing and selling chlor alkali and its derivatives. The company is also engaged in the trading of agrochemical products. The firm manufactures a range of products, such as chlorinated polyvinyl chloride (CPVC) resin, caustic soda, caustic potash, chlorine, hydrogen, chloromethanes, and hydrogen peroxide. The Company’s products are used in alumina, textile, crop protection, refineries, pharmaceutical, paper & pulp, soaps & detergent, and other industries. The Company’s subsidiaries include Meghmani Advanced Sciences Limited.

Frequently asked questions about Epigral

Analysts currently set an average price target of 2,040.00 INR for the Epigral stock (median: 2,040.00 INR), implying +103.2 % versus the latest price. The consensus is based on 7 analyst ratings.

7 analysts currently rate the Epigral stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Epigral to generate revenue of 24.75 B INR and earnings per share of 58.40 INR.

Converted at the current exchange rate, the Epigral share trades at 9.27 EUR (1,004.00 INR).

The expected revenue of Epigral is 24.75 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Epigral is 2.47 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Epigral is currently 17.19. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Epigral stock.

The price-to-sales ratio (P/S) of Epigral is currently 1.71. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Epigral stock.

The Eulerpool Quality Score for Epigral is 5/10.

The ISIN of Epigral is INE071N01016. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Epigral is EPIGRAL.NS. The ticker symbol is used to trade Epigral shares on the stock exchange.

Fair ValueTerminal
963.84 INR
Over-/UndervaluationTerminal
Fairly valued
Industry
Chemicals
Number of shares
Employees
Revenue per Employee
27.24 M INR
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
INR
Initial public offering
Aug 18, 2021
ISIN
INE071N01016
Cusip
Y5934N102
Market capitalization
42.41 B INRLarge Cap
52-Week Range
PEG
4.13
P/E ratio
P/Ee 2026
17.19
P/Ee 2027
12.50
P/Ee 2028
9.85
P/Ee 2029
15.35
P/S
P/Se
1.71
EV/EBIT
8.32
P/B Ratio
2.23
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
14.32 %
Dividend
Dividend yield
0.60 %
Est. Dividend Yield
0.70 %
Payout Ratio
7.09 %
Dividend growth Ø5Y
—
Dividend payments per year
2
Dividend paid since
3 years
Dividend not reduced since
3 years
Dividend increased since
1 year
Dividend withholding tax
20.00 %
Last updated Oct 9, 2026, 6:36 AM

Epigral Peer Group

Epigral Ticker

BSE · EPIGRAL.BO

Epigral FIGI

EPIGRAL:IN · BBG00645NFS1EPIGRAL:IB · BBG0110RD6X2EPIGRAL:IS · BBG0110RD6Z0

All fundamentals and in-depth analysis of Epigral

Our stock analysis for Epigral stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epigral. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.